Stock RCE RECCE PHARMACEUTICALS LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Market Closed - Australian S.E.
Other stock markets
 02:10:43 2024-05-01 am EDT 		5-day change 1st Jan Change
0.66 AUD 0.00% Intraday chart for Recce Pharmaceuticals Ltd +1.54% +23.36%
Apr. 17 Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice CI
Apr. 16 Recce Pharmaceuticals Advances Production of Anti-Infective Medication MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
RECCE PHARMACEUTICALS LTD Stock Recce Pharmaceuticals Ltd
+23.36% 87.41M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.00% 704B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.13% 577B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 348B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.53% 327B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.95% 288B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.77% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.93% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
A+
AMGEN INC. Stock Amgen Inc.
-4.89% 147B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. RCE Stock
  4. Ratings Recce Pharmaceuticals Ltd